Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)

Authors

Institutions

Publication Details

Journal
Neurology
Published
2025-04-07
DOI
https://doi.org/10.1212/wnl.0000000000211441
Citations
2
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)

Gary Romano, Adam L. Boxer, Megan J. Smithey, Lawrence Carter et al.
2 citations
Neurology
HER2/EGFR in Cancer Research
2.09
article

Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)

Gary Romano, Adam L. Boxer, Megan J. Smithey, Lawrence Carter, Leonardo Guizzetti, Bradley Boeve, Tiffany W. Chow, Giacomo Salvadore, Catherine J. Mummery, Barbara Borroni, Isabelle Le Ber, Julie Huang
article en
2 citations

Abstract

No abstract available for this paper.
NeurologyVol. 104(7_Supplement_1)
Allen Institute for Brain Science (US), University of California, San Francisco (US), WinnMed (US), Alector (United States) (US), Institut du Cerveau (FR), University College London (GB), University of Brescia (IT)
Zero hunger
Openalex Percentile: Top 13%
HER2/EGFR in Cancer Research
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005) — Gary Romano, Adam L. Boxer, et al. · Neurology (2025) | TGRS Research Map | TGRS